These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1345020)

  • 41. Postmarketing surveillance and other epidemiologic uses of drug prescription data in the United States.
    Strom BL
    Ann Ist Super Sanita; 1991; 27(2):235-7. PubMed ID: 1755576
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Drug safety. Gaps in the safety net.
    Couzin J
    Science; 2005 Jan; 307(5707):196-8. PubMed ID: 15653480
    [No Abstract]   [Full Text] [Related]  

  • 43. Postmarketing hepatic adverse event experience with PEGylated/non-PEGylated drugs: a disproportionality analysis.
    Hauben M; Vegni F; Reich L; Younus M
    Eur J Gastroenterol Hepatol; 2007 Nov; 19(11):934-41. PubMed ID: 18049161
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adverse drug reactions and reporting.
    Witte R
    Clin J Oncol Nurs; 2000; 4(4):181, 184. PubMed ID: 11261100
    [No Abstract]   [Full Text] [Related]  

  • 45. Pharmacovigilance: what to do if you see an adverse reaction and the consequences.
    Stenver DI
    Eur J Radiol; 2008 May; 66(2):184-6. PubMed ID: 18372136
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The quantification of drug risks in practice.
    Lee D; Bergman U
    WHO Reg Publ Eur Ser; 1993; 45():79-95. PubMed ID: 8442852
    [No Abstract]   [Full Text] [Related]  

  • 47. Methods for improving the reporting of adverse effects.
    Prescrire Int; 2011 Mar; 20(114):71. PubMed ID: 21648229
    [No Abstract]   [Full Text] [Related]  

  • 48. Pharmacogenomic profiling in postmarketing surveillance: prospects and challenges.
    Issa AM
    Pharmacogenomics; 2003 Sep; 4(5):647-55. PubMed ID: 12943471
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Drug surveillance].
    Kramer V
    Rev Med Chil; 1992 Sep; 120(9):1049-52. PubMed ID: 1340984
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Surveillance of radiopharmaceuticals in Latin American: an alert.
    Santos-Oliveira R; Smith SW; de Souza Albernaz M; Bordim JA; Antunes LJ
    Rev Esp Med Nucl; 2011; 30(2):134-6. PubMed ID: 21334775
    [No Abstract]   [Full Text] [Related]  

  • 51. [The role of drug registries in the post-marketing surveillance].
    Traversa G; Sagliocca L; Magrini N; Venegoni M
    Recenti Prog Med; 2013 Jun; 104(6):225-8. PubMed ID: 23801224
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Developing an optimal approach to global drug safety.
    Balkrishnan R; Furberg CD
    J Intern Med; 2001 Oct; 250(4):271-9. PubMed ID: 11576315
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The demise of postmarketing surveillance.
    Fletcher AP
    Adverse Drug React Toxicol Rev; 1995; 14(1):7-9. PubMed ID: 7612783
    [No Abstract]   [Full Text] [Related]  

  • 54. [Farmacovigilance: the way towards a safer drug use].
    Dobrić S
    Vojnosanit Pregl; 2007 Apr; 64(4):229-30. PubMed ID: 17580530
    [No Abstract]   [Full Text] [Related]  

  • 55. Enhancing postmarketing surveillance: continuing challenges.
    French DD; Margo CE; Campbell RR
    Br J Clin Pharmacol; 2015 Oct; 80(4):615-7. PubMed ID: 25869078
    [No Abstract]   [Full Text] [Related]  

  • 56. An audience with... Joanna F. Haas.
    Haas JF
    Nat Rev Drug Discov; 2005 Oct; 4(10):806. PubMed ID: 16237844
    [No Abstract]   [Full Text] [Related]  

  • 57. Global pharmacovigilance for antiretroviral drugs: overcoming contrasting priorities.
    Bakare N; Edwards IR; Stergachis A; Pal S; Holmes CB; Lindquist M; Duncombe C; Dodoo A; Novendstern J; Nwokike J; Kuchenbecker R; Aberg JA; Miller V; Strobos J
    PLoS Med; 2011 Jul; 8(7):e1001054. PubMed ID: 21750668
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Cutaneous drug reactions. A special challenge for dermatologists].
    Ständer S; Mockenhaupt M
    Hautarzt; 2014 May; 65(5):396. PubMed ID: 24820796
    [No Abstract]   [Full Text] [Related]  

  • 59. [Simplify and trivialize the reporting of adverse events].
    Warnet S
    Soins; 2015 Jun; Spec No():2S1. PubMed ID: 26506717
    [No Abstract]   [Full Text] [Related]  

  • 60. Postmarketing surveillance is needed.
    Srinivas VR
    BMJ; 2004 Jul; 329(7456):51. PubMed ID: 15231630
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.